Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 10, 2025Open Access

Real-World Predictors of Survival in CDK4/6 Inhibitor-Treated Metastatic Breast Cancer: The Significance of ER Expression Level and Treatment Naivety

View Full Paper
Ask AI
Bookmark
Share

Authors

BBBüşra BülbülBUBekir UcunCCCan Cangür

Discussion

Loading...

Member takes

Overview

Multicenter analysis reveals high estrogen receptor levels and treatment naivety improve survival in patients with HR-positive MBC.

Key Points

  • Higher overall survival rates are observed in patients without prior endocrine therapy.
  • Patients with ER expression ≥90% demonstrated longer overall survival compared to those with lower expression.
  • Assessment showed that not having received endocrine therapy and high ER expression are independent predictors for better overall survival.
  • The findings suggest using ER expression level as a potential biomarker for CDK4/6 inhibitor therapy response.

Cite This Study

Bülbül et al. (2025) studied this question.

synapsesocial.com/papers/68e861907ef2f04ca37e40e1https://doi.org/10.20944/preprints202509.2441.v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment consequence and adverse events of cyclin-dependent kinase 4/6 inhibitors on patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysis2025
  2. 2Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysis2025
  3. 3Comparative long-term outcomes of first-line CDK4/6 inhibitors plus endocrine therapy versus endocrine therapy in patients with HR+/HER2-metastatic or advanced breast cancer: a meta-analysis2025 · 4 citations
  4. 4Germline BRCA Mutation Affect the Clinical Outcomes of Metastatic Breast Cancer Treated with CDK4/6 Inhibitor: A Real-world Study2025
  5. 5Chemotherapy-Free Survival of CDK4/6 Inhibitor Combination Therapy or Endocrine Monotherapy as First-Line Treatment for HR+/HER2–Advanced Breast Cancer2025